The ten-year survival rate of breast cancer patients after receiving trastuzumab treatment cannot be generalized, and it is related to tumor type, clinical stage, physical condition and other factors. According to some statistics, the ten-year survival rate of stage I breast cancer is 70% to 85%; stage II is about 60%; stage III is 30% to 40%; and stage IV is only about 10%. Breast cancer is a common malignant tumor in women, and its development is related to many factors such as heredity and hormone levels. Trastuzumab, as a commonly used targeted therapy drug for HER-2 positive breast cancer patients, can be combined with surgery, radiotherapy, chemotherapy and other methods of co-treatment, which greatly prolongs the survival of patients. Nausea and vomiting, gastrointestinal discomfort and hair loss may occur during trastuzumab administration. The drug needs to be applied under the guidance of a doctor. Specific treatment can be consulted with professional physician’s opinion.